Browse Items · NEOMED Bibliography Database

Extracorporeal Membrane Oxygenation in Extreme Obesity: A Case Report and Review of the Literature.

The use of extracorporeal membrane oxygenation (ECMO) in the treatment of acute respiratory distress syndrome (ARDS) has been described as early as 1972 [Hill 1972]. Though a subsequent randomized trial showed no survival benefit over conventional…

Tags: *Extracorporeal Membrane Oxygenation, 2018, Adult, Adult/*complications/etiology/*therapy, Aspiration/complications, Azouz Vitali, Female, Firstenberg Michael, Hill Sarah, Humans, Morbid/*complications, Obesity, Pneumonia, Respiratory Distress Syndrome, The heart surgery forum

Serum Concentrations of Aerosolized Tobramycin in Medical, Surgical, and Trauma Patients

Tags: 2009, Antimicrobial agents and chemotherapy, Beam W B, Burdette S D, Journal Article or Conference Abstract Publication, Limkemann A J, Markert R J, Microbiology, Pharmacology & Pharmacy, Pneumonia, Slaughter J B

Ventilator-associated pneumonia: gearing towards shorter-course therapy

Purpose of review The studies that are reviewed in this article have all concluded that a shorter duration of antibiotic therapy (7-8 days) may be adequate in the treatment of the majority of patients with ventilator-associated pneumonia, and does…

Tags: 2006, antibiotic-therapy, antimicrobial therapy, Chua T D, Current opinion in infectious diseases, duration of therapy, File T M, Infection, Infectious Diseases, Journal Article or Conference Abstract Publication, Pneumonia, pseudomonas-aeruginosa, resolution, trial, ventilator-associated

A Structured Approach for Safely Reintroducing Bariatric Surgery in a COVID-19 Environment.

Due to the profound effect of novel coronavirus disease 2019 (COVID-19) on healthcare systems, surgical programs across the country have paused surgical operations and have been utilizing virtual visits to help maintain public safety. For those…

Disseminated Mycobacterium Haemophilum Infection And Pneumocystis Jirovecii Pneumonia In A Patient Receiving Immunosuppressive Therapy Case Report And Review Of Literature

Predictors of mortality for nursing home-acquired pneumonia: a systematic review.

BACKGROUND: Current risk stratification tools, primarily used for CAP, are suboptimal in predicting nursing home acquired pneumonia (NHAP) outcome and mortality. We conducted a systematic review to evaluate current evidence on the usefulness of…

The Effect Of Bilateral Superior Laryngeal Nerve Lesion On Swallowing: A Novel Method To Quantitate Aspirated Volume And Pharyngeal Threshold In Videofluoroscopy

The Science of Selecting Antimicrobials for Community-Acquired Pneumonia (CAP)

Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.

Streptococcus pneumoniae is the leading bacterial cause of community-acquired respiratory tract infections. Prior to the 1970s this pathogen was uniformly susceptible to penicillin and most other antimicrobials. However, since the 1990s there has…

Tags: 2006, Anti-Infective Agents/*therapeutic use, Bacterial, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Community-Acquired Infections/*drug therapy/economics/*microbiology, Department of Internal Medicine, Drug Resistance, File T M Jr, Fluoroquinolones/*therapeutic use, Humans, Ketolides/therapeutic use, Multiple, NEOMED College of Medicine, Pneumococcal/*drug therapy/economics/*microbiology, Pneumonia, Streptococcus pneumoniae/*growth & development

Overview of resistance in the 1990s.

The tremendous therapeutic advantage afforded by antibiotics is being threatened by the emergence of increasingly resistant strains of microbes. Selective pressure favoring resistant strains arises from misuse and overuse of antimicrobials (notably…

Tags: *Drug Resistance, 1999, Anti-Bacterial Agents/*therapeutic use, Bacterial/*drug therapy, Chest, Community-Acquired Infections/drug therapy, Cross Infection/drug therapy, Department of Internal Medicine, File T M Jr, Humans, Multiple, NEOMED College of Medicine, Pneumonia

New Diagnostic Tests for Pneumonia: What is Their Role in Clinical Practice?

The utility of diagnostic studies to determine the etiologic agents of community-acquired pneumonia has been controversial in part because of the lack of rapid, accurate, easily performed, and cost-effective methods. Advancements in molecular testing…

Community-acquired pneumonia: highlights of recent guidelines: how new recommendations may affect your practice.

The Infectious Diseases Society of America (IDSA) recently published updated guidelines for assessing and treating patients with community-acquired pneumonia. In contrast to the common practice of treating patients on the basis of clinical…

Tags: 1999, Community-Acquired Infections, Department of Internal Medicine, File T M Jr, Journal of Respiratory Diseases, NEOMED College of Medicine, Pneumonia, Pneumonia – Diagnosis, Risk Factors

Treating CAP caused by penicillin-resistant S pneumoniae.

Over the last decade, the incidence of penicillin resistance among Streptococcus pneumoniae isolates has markedly increased. This trend is unsettling because infections caused by S pneumoniae are among the leading causes of morbidity and mortality in…

Tags: 1999, Bacterial, Bacterial – Diagnosis, Community-Acquired Infections, Department of Internal Medicine, Diagnosis, Differential, Drug Resistance, File T M Jr, Journal of Respiratory Diseases, Microbial, NEOMED College of Medicine, Pneumonia, Streptococcal Infections

Community-acquired pneumonia.

Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.

Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient…

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of…

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection.

Infections caused by M. pneumoniae, C. pneumoniae, and Legionella spp. are important causes of community-acquired pneumonia (CAP). In the past decade, considerable new information has come to light concerning these organisms. Despite this, debate…

Management Of Community-acquired Pneumonia: An Appropriate-use Tool

The Importance Of Chlamydia Pneumoniae As A Pathogen: The 1996 Consensus Conference On Chlamydia Pneumoniae Infections

Rapid Detection Of Streptococcus Pneumoniae In Community-acquired Pneumonia

Tags: 2006, adults, antimicrobial therapy, bacteremic pneumococcal pneumonia, cerebrospinal-fluid, Clinical Microbiology and Infection, Diagnosis, File T M, Infections, Infectious Diseases, Kozlov R S, Management, Microbiology, Pneumococcus, Pneumonia, polymerase chain-reaction, rapid detection, sputum culture, urinary antigen test

The science of selecting antimicrobials for community-acquired pneumonia (CAP).

BACKGROUND: Among infectious diseases, community-acquired pneumonia (CAP) is the leading cause of death in the United States and is associated with a substantial economic burden to the health care system. Initiating appropriate empiric therapy can be…

New diagnostic tests for pneumonia: what is their role in clinical practice?

The utility of diagnostic studies to determine the etiologic agents of community-acquired pneumonia has been controversial in part because of the lack of rapid, accurate, easily performed, and cost-effective methods. Advancements in molecular testing…

Tags: 2011, Antigens, Bacterial/*diagnosis/metabolism, Bacterial/urine, Calcitonin/blood, Clinics in chest medicine, Community-Acquired Infections/*diagnosis/metabolism/*microbiology/virology, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Nucleic Acid Amplification Techniques, Pneumonia, Polymerase Chain Reaction, Protein Precursors/blood, Viral/*diagnosis/metabolism

A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia.

The goals of optimal antimicrobial therapy are to treat infection effectively, to improve the clinical condition of the patient, and to prevent the emergence of resistant bacterial strains. For ideal drug usage the World Health Organization…

Tags: 2003, Clinical cornerstone, Community-Acquired Infections/*drug therapy, Department of Internal Medicine, File Thomas M Jr, Fluoroquinolones/*administration & dosage/pharmacology/therapeutic use, Humans, NEOMED College of Medicine, Ofloxacin/administration & dosage/pharmacology/therapeutic use, Pneumococcal/*drug therapy, Pneumonia, Safety, Time Factors, Treatment Outcome

Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.

The beta-lactam antibiotics (penicillins and cephalosporins) are commonly prescribed for the treatment of community-acquired pneumonia. However, Streptococcus pneumoniae, the most common etiologic agent of community-acquired pneumonia, has become…

Tags: *beta-Lactam Resistance, 2002, beta-Lactams/economics/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Contraindications, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumococcal/*drug therapy/economics/pathology, Pneumonia, Practice Guidelines as Topic, Streptococcus pneumoniae/*drug effects/metabolism

Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.

Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future…

Tags: *Practice Guidelines as Topic, 2010, Anti-Bacterial Agents/*therapeutic use, Bacteria/drug effects/isolation & purification, Bacterial/diagnosis/*drug therapy, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Clinical Trials as Topic, Cross Infection/diagnosis/*drug therapy, Department of Internal Medicine, File Thomas M Jr, Hospitals, Humans, Microbial Sensitivity Tests, NEOMED College of Medicine, Pneumonia, Time Factors, Ventilator-Associated/diagnosis/*drug therapy

Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia.

Tags: *Methicillin Resistance, 2005, Anti-Bacterial Agents/pharmacology, Bacterial/*epidemiology/*microbiology, Community-Acquired Infections, Current opinion in infectious diseases, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Staphylococcal Infections/*epidemiology, Staphylococcus aureus/*drug effects

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment…

Tags: 2017, 80 and over, Adult, Aged, Anti-Bacterial Agents/adverse effects/*therapeutic use, Atypical pathogen, Bacterial/*drug therapy, Ceftaroline fosamil, Ceftriaxone/adverse effects/*therapeutic use, Cephalosporins/adverse effects/*therapeutic use, Chlamydial Pneumonia, Chlamydophila pneumoniae, Clinical Trials, Combination/adverse effects/methods, Community-Acquired Infections/*drug therapy, Community-acquired pneumonia, Department of Internal Medicine, Double-Blind Method, Drug Therapy, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Humans, International journal of antimicrobial agents, Legionella pneumophila, Llorens Lily, Macrolide, Macrolides/adverse effects/*therapeutic use, Male, Middle Aged, Mycoplasma, Mycoplasma pneumoniae, NEOMED College of Medicine, Phase III as Topic, Pneumonia, Randomized Controlled Trials as Topic, Talbot George H, Time Factors, Treatment Outcome

Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.

Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient…

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant…

Tags: *Treatment Outcome, 2002, 80 and over, Adolescent, Adult, Aged, Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use, Amoxicillin/adverse effects/therapeutic use, Bacterial, Bacterial/drug therapy/immunology, Bronchitis/drug therapy/microbiology, Combination/adverse effects/*therapeutic use, Department of Internal Medicine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Female, File Thomas M Jr, Follow-Up Studies, Humans, International journal of antimicrobial agents, Jacobs Michael R, Male, Microbial Sensitivity Tests, Middle Aged, Multicenter Studies as Topic, NEOMED College of Medicine, Pneumonia, Poole Michael D, Respiratory Tract Infections/*drug therapy/metabolism/microbiology, Streptococcal Infections/*drug therapy/metabolism/microbiology, Streptococcus pneumoniae/*drug effects, Wynne Brian

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and…

Tags: 2011, 80 and over, Aged, Bacteria, Bacteria/isolation & purification, Bacterial – Drug Therapy, Bacterial/*drug therapy, Ceftriaxone – Administration and Dosage, Ceftriaxone – Adverse Effects, Ceftriaxone/administration & dosage/adverse effects, Cephalosporins – Administration and Dosage, Cephalosporins – Adverse Effects, Cephalosporins/*administration & dosage/*adverse effects, Community-Acquired Infections – Drug Therapy, Community-Acquired Infections/*drug therapy, Critchley Ian A, Department of Internal Medicine, Double-Blind Method, Double-Blind Studies, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Human, Humans, Infusions, Intravenous, Lee Jon, Llorens Lily, Low Donald E, Male, Middle Age, Middle Aged, NEOMED College of Medicine, Pneumonia, RANDOMIZED controlled trials, Talbot George H, The Journal of antimicrobial chemotherapy, Thye Dirk A, Treatment Outcome, Treatment Outcomes

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

BACKGROUND: Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated…

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.

OBJECTIVES: Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP. PATIENTS AND…

Burden of community-acquired pneumonia in North American adults.

To determine the burden of community-acquired pneumonia (CAP) affecting adults in North America, a comprehensive literature review was conducted to examine the incidence, morbidity and mortality, etiology, antibiotic resistance, and economic impact…

Tags: 2010, Adult, Bacterial – Economics, Bacterial – Epidemiology, Bacterial – Microbiology, Bacterial – Mortality, Bacterial – Prevention and Control, Bacterial/economics/*epidemiology/microbiology/prevention & control, Community-Acquired Infections – Economics, Community-Acquired Infections – Epidemiology, Community-Acquired Infections – Microbiology, Community-Acquired Infections – Prevention and Control, Community-Acquired Infections/economics/epidemiology/microbiology/prevention & control, Cost of Illness, Department of Internal Medicine, Economic Aspects of Illness, File Thomas M Jr, Health Care Costs, Health Status Indicators, Hospitalization – Economics, Hospitalization – Statistics and Numerical Data, Hospitalization/economics/statistics & numerical data, Human, Humans, Incidence, Length of Stay – Statistics and Numerical Data, Length of Stay/statistics & numerical data, Marrie Thomas J, NEOMED College of Medicine, North America, North America/epidemiology, Pneumococcal Vaccine, Pneumococcal Vaccines, Pneumococcal/economics/epidemiology/mortality/prevention & control, Pneumonia, Postgraduate medicine, Risk Factors, Streptococcus, Streptococcus pneumoniae

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.

OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter,…

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen…

Tags: *Anti-Bacterial Agents/pharmacokinetics/therapeutic use, *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control, *Models, *Pneumonia, 2009, Adelman Martin H, Aged, Area Under Curve, Bacterial/drug therapy/microbiology/physiopathology/prevention & control, Biological, Bronchitis, Chronic Obstructive/drug therapy/microbiology/*physiopathology, Chronic/drug therapy/microbiology/physiopathology, Department of Internal Medicine, Disease Progression, Female, File Thomas M Jr, Humans, International journal of antimicrobial agents, Klugman Keith P, Lavin Bruce, Lung Diseases/complications/drug therapy/microbiology, Lung/microbiology, Male, Microbial Sensitivity Tests, Middle Aged, Monte Scott V, NEOMED College of Medicine, Paladino Joseph A, Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control, Pneumonia, Pulmonary Disease, Schentag Jerome J, Severity of Illness Index, Singer Mendel E, Streptococcus pneumoniae/*drug effects, Yu Victor L

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

BACKGROUND: Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with…

Tags: *clinical trial, *Community-acquired, *Pneumonia, *solithromycin, *Streptococcus pneumoniae, 2016, 80 and over, Administration, Adult, Aged, Anti-Bacterial Agents/*administration & dosage/adverse effects, Bacterial, Bacterial/diagnosis/*drug therapy/*microbiology, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/diagnosis/*drug therapy/*microbiology, Comorbidity, Das Anita F, Department of Internal Medicine, Drug Resistance, Female, Fernandes Prabhavathi, File Thomas M Jr, Fluoroquinolones/*administration & dosage/adverse effects, Gonong Joven Roque V, Humans, Intravenous, Jamieson Brian D, Keedy Kara, Macrolides/*administration & dosage/adverse effects, Male, Microbial Sensitivity Tests, Middle Aged, Moxifloxacin, NEOMED College of Medicine, Oldach David, Oral, Pneumonia, Rewerska Barbara, Sheets Amanda, Taylor David, Treatment Outcome, Triazoles/*administration & dosage/adverse effects, Vucinic-Mihailovic Violeta

What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.

There are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of the drug effect of antimicrobial therapy for mild community-acquired pneumonia (CAP). However, there is evidence that ineffective…

Tags: *Research Design, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/*drug therapy/microbiology, Department of Internal Medicine, Disease Progression, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumococcal/*drug therapy/microbiology, Pneumonia, Randomized Controlled Trials as Topic/*methods, Schentag Jerome J, Streptococcus pneumoniae/*isolation & purification, Time Factors, Treatment Outcome

Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs.

International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

The significance of community-acquired pneumonia (CAP) has led to the publication of guidelines from numerous international organisations. Because the macrolide class of antimicrobials is active against most of the key pathogens associated with CAP,…

Summary of ceftaroline fosamil clinical trial studies and clinical safety.

In October 2010, the new cephalosporin, ceftaroline fosamil, was approved by the US Food and Drug Administration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The active…

Tags: 2012, Anti-Bacterial Agents/adverse effects/*therapeutic use, Bacterial/drug therapy, Cephalosporins/adverse effects/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Clinical Trials as Topic, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Staphylococcal Skin Infections/drug therapy, Stein Gary E, Wilcox Mark H

Browse Items (66 total)